Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Observer-blind, Active-control Study to Evaluate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age

NCT06864143 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT06864143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06864143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Observer-blind, Active-control Study to Evaluate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
Lead sponsor
ModernaTX, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 7, 2025
Completion date
October 13, 2025
Enrollment
1,320 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, sars-cov-2